Treating respiratory patients systemically can lead to unwanted effects in the body owing to a lack of specificity and the need for high doses. At Pulmocide, we aim to deliver novel respiratory treatments easily and directly to the lung to maximize efficacy and minimize adverse effects.
More
Well toleratedLow risk of adverse effects
Poorly toleratedHigh risk of adverse effects
Pulmocide develops inhaled medicines to target the site of disease in the lung with minimal systemic exposure
The small molecules accumulate in the lung for sustained treatment
Conventional systemic therapy requires a much higher dosage
This is poorly tolerated, and has a high risk of adverse effects
This approach is ineffective at treating disease on the surface of the lung
We have identified pulmonary aspergillosis as a disease with high unmet medical need and the opportunity to treat patients in a safe and effective manner with potent inhaled therapeutics.
Pulmocide was built by Garth Rapeport and Pete Strong, who have a proven success record with Respivert (acquired by Janssen Biotech, Inc. in 2010) and previously at GSK.
The latest Company news, product news, and details of upcoming conferences and events.
We are developing novel, potent first-in-class anti-infective agents for delivery by inhaled administration for life-threatening lower respiratory infections.
